The Lancet. Respiratory medicine
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
Immunotherapy in COVID-19: why, who, and when?
The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?
Geography, generalisability, and susceptibility in clinical trials.
Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?
